Xolair® (brand name for omalizumab) received U.S. approval for reducing reactions to foods after accidental exposure. Xolair is the first approved medication for food allergy.
While there is excitement by the possibilities for Xolair, it’s important to understand what the treatment delivers. Hear directly from the senior investigator involved with OUtMATCH, the clinical trial which assessed this medication and led to its approval in the U.S.
What the webinar is about: Learn what Xolair is and how it works, who the target patient is for this medication, along with the objectives, treatment protocols and results of the OUtMATCH clinical trial. There will also be a discussion on the importance of this first step in paving the way for future food allergy treatments.
Who is presenting: Dr. Sharon Chinthrajah, Acting Director of the Sean N. Parker Center for Allergy and Asthma Research where she leads the team to conduct novel and impactful Phase 1-3 translational studies in food allergy, asthma, allergic rhinitis, atopic dermatitis, COVID and influenza. Dr. Chinthrajah received her MD from Drexel University College of Medicine, completed her Internal Medicine training and a chief residency at California Pacific Medical Center, and sub-specialized in Pulmonary/Critical Care and Allergy/Immunology at Boston Medical Center.
When was the webinar: Friday, April 5, 2024 at 12:30-1:30 pm EDT.
Obtenez des renseignements essentiels sur les allergies directement dans votre boîte de réception
